Avita Medical (51KA) Stock Price & Analysis
51KA Stock Chart & Stats
- Day’s Range
- EUR 13.50 - EUR 14.60
- 52-Week Range
- EUR 2.68 - EUR 15.10
- Previous Close
- EUR 13.80
- Volume
- N/A
- Average Volume (3M)
- 351
- Market Cap
- EUR 421.26M
- Enterprise Value
- EUR 164.34M
- Total Cash (Recent Filing)
- EUR 11.13M
- Total Debt (Recent Filing)
- EUR 48.48M
- Price to Earnings (P/E)
- ―
- Beta
- 1.33
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.21
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Rapid revenue growth and the raised FY2026 outlook indicate expanding commercial adoption of the company’s products. Continued sequential gains can improve operating leverage, support broader clinical penetration, and create a stronger base for reaching sustainable cash generation.
High Gross Margins
Stable gross margins above 80% show attractive product-level economics even as the portfolio expands. Flat-to-lower operating expenses alongside rising revenue provide evidence of potential operating leverage, which could make future revenue growth more valuable to earnings.
RECELL Adoption And Reimbursement Progress
RECELL’s rising U.S. utilization supports durable procedure-based consumables demand, while proposed national reimbursement values could improve payment transparency. Together, adoption and clearer coding may reduce commercialization friction and broaden provider willingness to use the platform.
Bears Say
Persistent Unprofitability
The company’s strong revenue and gross margin have not yet translated into profitability because operating costs remain substantial. Persistent losses constrain internally funded growth and leave execution dependent on achieving further scale, cost discipline, and the planned break-even trajectory.
Negative Equity And Funding Dependence
Negative equity and modest liquidity reduce financial flexibility while the business remains cash-consuming. The additional financing tranche depends on reaching a revenue threshold, so any shortfall in commercial execution could increase funding pressure before internally generated cash becomes available.
PermeaDerm Remains Early Stage
PermeaDerm has not yet become a meaningful contributor to revenue, limiting the near-term diversification benefit of the broader product portfolio. Its future impact depends on clinical follow-through and customer adoption, creating execution uncertainty around an important growth opportunity.
Avita Medical News
Avita Medical’s PermeaDerm Trial Completion: What It Means for RCEL Investors
Avita Medical Ltd ($RCEL) announced an update on their ongoing clinical study. Avita Medical Ltd (RCEL) has completed a post‑market clinical study called “A Prospective Post‑Market Multicenter Randomized Controlled Clinical
51KA FAQ
What was Avita Medical’s price range in the past 12 months?
What is Avita Medical’s market cap?
When is Avita Medical’s upcoming earnings report date?
How were Avita Medical’s earnings last quarter?
Is Avita Medical overvalued?
Does Avita Medical pay dividends?
What is Avita Medical’s EPS estimate?
How many shares outstanding does Avita Medical have?
What happened to Avita Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Avita Medical?
What is the TipRanks Smart Score and how is it calculated?
Avita Medical Stock Smart Score
Company Description
Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Cary G. Vance
- Employees
- 226
- Website
- avitamedical.com
- Address
- 28159 Avenue Stanford, Valencia, CA, 91355, US
Avita Medical (51KA) Earnings & Revenues
51KA Company Deck
51KA Earnings Call
Earnings Call SentimentPositive
The call conveyed strong commercial momentum: record quarterly revenue, meaningful sequential growth across RECELL (U.S. and international), early traction for Cohealyx, high gross margins (~82%), reduced cash burn, and an upwardly revised FY26 revenue guide with a stated path to cash flow breakeven in Q4 2026. Key risks remain: PermeaDerm is still nascent, the company remains unprofitable with relatively modest cash on hand ($11.1M), access to additional financing is contingent on achieving revenue milestones, and final reimbursement/coding changes (though largely positive) carry implementation risk. Overall, the positives — revenue acceleration, margin strength, improved cash dynamics, and guidance raise — outweigh the remaining execution and financing risks.
View all DE:51KA earnings summaries51KA Net sales Breakdown
- 99.27% Commercial sales
- 0.67% Services for emergency preparedness
- 0.07% Deferred commercial revenue
51KA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |
